Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hanmi Holdings Co., Ltd.

Spectrum Pharmaceuticals, Inc.

Hanmi Pharmaceutical Co., Ltd.

Tae Hee Ha

Kwee Hyun Suh

Hee Sook Oh

Gwan Sun Lee

Chang Hee Park

Ji Young Jeon

Young Hoon Kim

Eun Young Kim

Won Jeoung Kim

Eun Joo Kwak

Kwang Ok Lee

Jae Hyuk Jung

Jong Ouk Baek

Maeng Sup Kim

Mi Young Cha

Mi Ra Kim

Ju Yeon Lee

Myoung Gi Jo

Hee Seok Kim

Jae Chul Lee

Seok Jong Kang

Kwee-Hyun Suh

Young Ho Moon

Ho Seok Kim

Sun Young Jang

Guru Reddy

Kyoung Soo Kim

Han Kyong Kim

Eun Sook Kim

Wan Joo Kim

Nam Du Kim

Sangmin Yun

Hee Cheol Kim

Hee Seock Kim

Wook Jang

Ki Byung Chai

Jung Ae Shin

Kweehyun Suh

Won Jeong Kim

Sun Young Jung

Chang Hee Dongho-Villa 203 Park

Provided are crystalline forms of acid addition salts of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)furo[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and a pharmaceutical composition including the same. The crystalline forms may be easily used in preparing the pharmaceutical composition including the same as an active ingredient.

Crystal form of acid addition salt of furopyrimidine compound

This patent document relates to the crystalline forms of a quinazoline compound and the hydrochloride salts thereof. More particularly, this patent document relates to a preparation method of the crystalline forms of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one and its hydrochloride salts.

Crystalline forms of a quinazoline compound and its hydrochloride salts

A crystalline form of an alkyl benzene sulfonyl urea compound that is useful as an oral antidiabetics is disclosed. Specifically, the compound is a hydrochloride salt of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide of the following formula I. A pharmaceutical composition containing the compound is also disclosed: 

Crystalline forms of hydrochloride salts of thienopyrimidine compound

The present invention relates to crystalline forms of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and pharmaceutical compositions containing the same. The crystalline forms can be easily used for the preparation of a pharmaceutical composition containing the same as an active ingredient.

Crystalline forms of thienopyrimidine compound

The present invention relates to a novel method for preparing thienopyrimidine compound having an activity of selectively inhibiting tyrosine kinase, specifically the mutant epidermal growth factor receptor tyrosine kinase; and a novel intermediate used therein. According to the method of the present invention, the industrial mass-production of the compound of Formula 1, which is useful as a therapeutic agent for non-small cell lung cancer induced by the mutant epidermal growth factor receptor tyrosine kinase, can be implemented more conveniently and efficiently than the conventional technology.

Process for preparing thienopyrimidine compound and intermediates used therein

A method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase. Intermediates used in the method are provided.

Method for preparing thienopyrimidine compound and intermediates used therein

The present invention provides a novel method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase, and novel intermediates used in the method.

The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

Fused pyrimidine derivatives for inhibition of tyrosine kinase activity

Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.

Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same

This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.

Optically pure esomeprazole and its salt can be simply prepared by dissolving (S)-(&#x2212;)-binol, a weak base and the racemic form of omeprazole in a mixture of a water-compatible organic solvent and water at a high temperature, cooling the mixed solution to crystallize the inclusion complex of esomeprazole and (S)-(&#x2212;)-binol, and removing the (S)-(&#x2212;)-binol moiety from the crystallized inclusion complex.

Method of preparing esomeprazole and salts thereof

Growing community of inventors

Hwaseong-si, South Korea

Tae Hee Ha